Escin Compounds Induce Premature Termination Codon Read-Through
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis (CF) caused by nonsense mutations, such as those leading to premature termination codons (PTCs) in the CFTR gene, lack an optimal combination of efficacy and safety, with existing pharmacologic approaches like aminoglycosides showing mixed results and toxicity issues, necessitating the development of non-toxic, orally bioavailable read-through agents.
Innovation Solution
Identification and evaluation of clinically approved compounds, including escin, which demonstrate read-through efficacy and stability of mRNA transcripts containing PTCs, to promote the translation of functional CFTR protein, thereby addressing the limitations of existing treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If aminoglycosides are used to promote read-through of PTCs, then translation suppression is achieved, but toxicity increases and long-term use is not suitable
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of aminoglycoside compounds to create derivatives with improved properties. Specifically, the invention optimizes the amino sugar components and glycosidic bond configurations to enhance ribosomal binding affinity while reducing off-target toxicity effects, thereby maintaining read-through efficacy at lower doses with improved safety profiles
Solution Approach 2:
The patent creates synthetic copies of natural aminoglycoside structures with modified properties. By replicating the core mechanism of action (ribosomal binding) while copying and optimizing specific structural features, the invention produces compounds that maintain therapeutic effectiveness but with reduced harmful side effects, enabling safer long-term treatment
2Reliability
If synthetic aminoglycoside derivatives are used to improve read-through, then read-through efficacy increases and toxicity reduces, but oral bioavailability may be compromised
Solution Approach 1:
The patent applies parameter changes by systematically modifying physicochemical properties of the compounds including molecular weight, lipophilicity, and charge distribution. These parameter optimizations enable the derivatives to maintain sufficient stability for oral administration while preserving their ability to reach target tissues and exert read-through effects
Solution Approach 2:
The patent introduces intermediary structures that facilitate oral absorption. By incorporating specific functional groups and molecular features that act as intermediaries between the compound and biological membranes, the invention enhances oral bioavailability while maintaining the core mechanism of PTC suppression
3Ease of operation
If ataluren is used for read-through induction, then oral bioavailability is achieved, but efficacy is limited in patients using chronic inhaled tobramycin
Solution Approach 1:
The patent extracts and optimizes the essential read-through inducing properties from ataluren and other compounds, then combines them with complementary mechanisms. By isolating the core functional elements and removing limitations, the invention creates compounds that maintain oral bioavailability while overcoming interference from concurrent antibiotic use
Solution Approach 2:
The patent employs composite molecular structures that combine multiple functional elements. By integrating different pharmacological activities and mechanisms of action into single compound molecules, the invention achieves read-through induction that is less susceptible to interference from other medications while maintaining oral administration capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Escin and other identified compounds effectively induce read-through of PTCs, increasing CFTR conductance and protein expression, offering a potentially safer and more effective treatment option for CF patients by stabilizing mRNA transcripts and enhancing CFTR function.
Implementation Method 1
stability of mRNA transcripts containing PTCs
Implementation Method 2
an amino acid carried by near-cognate aminoacyl tRNA is inserted into a polypeptide chain at the erroneous stop codon, allowing translation to continue
Implementation Method 3
increasing CFTR conductance and protein expression
Data Source
AI summary
The present disclosure provides compositions and methods for treating and/preventing diseases and conditions associated with premature termination mutations. The methods disclosed herein comprise the step of administering to the subject a therapeutically effective dose of a compound described herein that induces read-through of the premature termination codon. The methods of the present disclosure may further comprise treating the subject with enzyme replacement therapy wherein the enzyme replacement therapy is selected for the disease or condition to be treated. Furthermore, the present disclosure provides method of pharmacologically suppressing premature termination codons in a subject in need of such suppression.